Results 41 to 50 of about 57,449 (202)

A Case Study of Pain Management at End-of-Life for a Patient on High-Dose Buprenorphine

Journal of Patient Experience, 2022
In Australia, high-dose sublingual buprenorphine and long-acting injectable buprenorphine are available. High-dose buprenorphine is used predominantly in the setting of opioid use disorder and has a role in chronic pain.
Naomi T Katz, Martyn Lloyd-Jones, Lucy Demediuk, Kerry McLaughlin, Megan McKechnie, Michelle Gold   +5 more
doaj   +1 more source

Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021

Drug and Alcohol Dependence Reports, 2023
Background: Amidst an unprecedented overdose epidemic, the opioid partial agonist buprenorphine is a medication for opioid use disorder associated with reductions in overdose.
Brandon del Pozo, Danielle Atkins, Barbara Andraka-Christou, Rachel Wightman, M H Clark, Philip Huynh, Bradley Ray   +6 more
doaj   +1 more source

Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims

Drug and Alcohol Dependence Reports, 2023
Background: As the overdose crisis continues in the U.S. and Canada, opioid use disorder (OUD) treatment outcomes for people with co-occurring psychiatric disorders are not well characterized.
Kevin Y Xu, Vivien Huang, Arthur Robin Williams, Caitlin E Martin, Alexander R. Bazazi, Richard A. Grucza   +5 more
doaj   +1 more source

Buprenorphine, oxycodone, hydrocodone, and methadone mortality in the United States (2010‒2017)

Journal of the American College of Emergency Physicians Open
Objective Opioid overdose survivors present to emergency departments (EDs) and many EDs have developed programs to initiate buprenorphine. The impact of the increasing use of buprenorphine in ED and by other providers is unknown while opioid mortality ...
Karilynn M. Rockhill, Gabrielle E. Bau, Angela DeVeaugh‐Geiss, Howard Chilcoat, Richard Dart, Janetta Iwanicki, Joshua C. Black   +6 more
doaj   +1 more source

Naloxone and Metabolites Quantification in Cord Blood of Prenatally Exposed Newborns and Correlations with Maternal Concentrations

American Journal of Perinatology Reports, 2016
Objective To quantify naloxone and metabolite concentrations in newborns prenatally exposed to sublingual buprenorphine/naloxone and to correlate neonatal and maternal metabolite concentrations.
Samantha L. Wiegand, Madeleine J. Swortwood, Marilyn A. Huestis, John Thorp, Hendreé E. Jones, Neeta L. Vora   +5 more
doaj   +1 more source

Retrospective analysis of heroin detoxification with buprenorphine in a psychiatric hospital in Japan

Neuropsychopharmacology Reports, 2020
Aim We assessed the efficacy of buprenorphine replacement taper therapy in a psychiatric hospital in Japan. Methods Based on the medical records, a retrospective analysis was performed to evaluate the outcomes of buprenorphine replacement taper therapy ...
Tatsushi Nagano, Sohei Kimoto, Katsuro Aso, Takashi Komori, Yasunari Yamaguchi, Kazuya Okamura, Noriya Yamamoto, Toshifumi Kishimoto   +7 more
doaj   +1 more source

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder

Acta Obstetricia et Gynecologica Scandinavica, 2023
Introduction Current WHO guidelines recommend using methadone or buprenorphine as maintenance treatments for maternal opioid use disorder. However, buprenorphine‐naloxone, with a lower abuse risk than buprenorphine monotherapy or methadone, offers a ...
Minna M. Kanervo, Sarimari J. Tupola, Eeva M. Nikkola, Krista M. Rantakari, Hanna K. Kahila   +4 more
doaj   +1 more source

Development of opioid analgesic tolerance in rat to extended-release buprenorphine formulated for laboratory subjects.

PLoS ONE
Buprenorphine in an extended-release formulation intended for use in laboratory subjects is frequently administered to rats to provide extended analgesia without repeated handling.
Christina M Larson, Cecilia Barajas, Kelley F Kitto, George L Wilcox, Carolyn A Fairbanks, Cristina D Peterson   +5 more
doaj   +1 more source

Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims

Addiction Science & Clinical Practice
Background Potential differences in buprenorphine treatment outcomes across various treatment settings are poorly characterized in multi-state administrative data.
Kevin Y. Xu, Alex K. Gertner, Shelly F. Greenfield, Arthur Robin Williams, Richard A. Grucza   +4 more
doaj   +1 more source

Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France

Substance Abuse Treatment, Prevention, and Policy, 2017
Background Injectable opioids are an interesting option for people who inject drugs (PWID) that do not respond to oral Opioid Maintenance Treatment (OMT).
Perrine Roux, Daniela Rojas Castro, Khadim Ndiaye, Laélia Briand Madrid, Virginie Laporte, Marion Mora, Gwenaelle Maradan, Stéphane Morel, Bruno Spire, Patrizia Carrieri   +9 more
doaj   +1 more source